VEA
GMAB icon

Virtus ETF Advisers’s Genmab GMAB Stock Holding History

Virtus ETF Advisers’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$827K Buy
30,830
+3,335
+12% +$99.9K 0.38% 55
2025
Q4 		$847K Hold
27,495
– – 0.4% 56
2025
Q3 		$843K Hold
27,495
– – 0.46% 54
2025
Q2 		$568K Buy
+27,495
New +$564K 0.35% 81

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Virtus ETF Advisers's GMAB Position: Q1 2026 in Review

Virtus ETF Advisers increased its Genmab (GMAB) stake by 12% in Q1 2026, buying an estimated $99.9K and bringing the position to 30,830 shares worth $827K. The position accounts for 0.38% of the portfolio, ranked #55.

Virtus ETF Advisers first reported a position in GMAB in Q2 2025 and has held it in 4 quarters since. The position peaked at $847K in Q4 2025. 272 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • Virtus ETF Advisers held 30,830 shares of Genmab worth $827K as of Q1 2026.
  • Virtus ETF Advisers bought 3,335 Genmab shares in Q1 2026, an estimated $99.9K.
  • Genmab made up 0.38% of Virtus ETF Advisers's portfolio in Q1 2026, its #55 holding.
  • Virtus ETF Advisers first reported a position in Genmab in Q2 2025 and has held it in 4 quarters since.
  • Virtus ETF Advisers's Genmab position peaked at $847K in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Virtus ETF Advisers's 13F filing for Q1 2026, filed 14 May 2026.